Hypercalcemia in hypoparathyroidism has rarely been described. A 55 year-old male patient with primary hypoparathyroidism, left eye melanoma, and Noonan's syndrome, was referred to the endocrinology clinics due to hypoparathyroidism. Laboratories showed serum calcium of 7.8 mg/d, and phosphate 4.8 mg/dl, while using calcium carbonate 1200 mg and vitamin D3 600 IU daily. Calcitriol 0.25 mcg daily was started and calcium carbonate discontinued. Abdominopelvic CT scan and thoracolumbar MRI, showed metastasis to liver, pancreas, and osteolytic lesions in spine, humerus, and ribs. Liver biopsy confirmed metastatic melanoma. Eight weeks later, serum calcium increased to 12 mg/dl. PTH, vitamin D 1,25-OH and PTHrP levels were within the lower range of normal compatible with hypercalcemia of malignancy, secondary to osteolytic disease. Zoledronic acid was added to treat hypercalcemia and bone pain. Our case demonstrates a successful treatment and monitoring of hypocalcemia after administration of bisphosphonate in a patient with hypoparathyroidism.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Atypical parathyroid tumor: A rare cause of primary hyperparathyroidism in an adolescent.
Arch Argent Pediatr
January 2025
Hospital Italiano de Buenos Aires, City of Buenos Aires, Argentina.
Hyperparathyroidism is a rare entity in pediatrics. It is defined as the increased production of parathyroid hormone. It may be due to a primary defect of the parathyroid glands (primary hyperparathyroidism) or to a compensatory parathyroid hormone production to correct hypocalcemia states of various origins (secondary hyperparathyroidism).
View Article and Find Full Text PDF[Albumin adjustment of total serum calcium - is it worth doing?].
Probl Endokrinol (Mosk)
November 2024
Calcium is the most abundant mineral in the human body. About 99% of calcium is deposited in the bones in the form of hydroxyapatite and only 1% is located in the intracellular and extracellular fluid. Ionized calcium, which makes up about 50% of the total amount of circulating calcium, is biologically active; the remaining percentage is bound to plasma proteins (40%, of which albumin accounts for 90%, and globulins for 10%), or is in complex with anions (10%) such as citrate, lactate, bicarbonate, phosphate.
View Article and Find Full Text PDFSevere Hypercalcemia Following Hip Joint Implantation of Calcium Sulfate Antibiotic Beads: Case Series and Review of Literature.
J Community Hosp Intern Med Perspect
January 2025
Division of Hospital Medicine, Johns Hopkins Community Physicians, Johns Hopkins Medicine, Baltimore, MD, USA.
Purpose: The diagnosis and management of hypercalcemia in hospitalized patients can be challenging. Hypercalcemia is often associated with significant morbidity and end-organ damage which may delay a patient's recovery.
Methods: We report a case series of three patients who underwent orthopedic procedures with intraoperative placement of vancomycin-loaded calcium sulfate beads.
Epitheliotropic T-cell lymphoma of non-viral origin with hypercalcemia of malignancy in a Roman goose (Anser anser domesticus).
Res Vet Sci
January 2025
Department of Veterinary Medicine, University of Perugia, 06126 Perugia, Italy.
A Roman goose (Anser anser domesticus) was presented with a large mass on the left lateral side of the neck with a smaller satellite mass on the right. Utilizing radiography, blood tests, and histological and immunohistochemical investigations, a diagnosis of cutaneous T-cell lymphoma associated with hypercalcemia of malignancy was established. The involvement of oncogenic viruses was ruled out through PCR and RT-PCRs.
View Article and Find Full Text PDFIs There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
Biomedicines
January 2025
Division of Hematology, University Hospital Centre Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia.
Multiple myeloma (MM) is a hematologic disease characterized by the clonal expansion of malignant plasma cells that accumulate in the bone marrow, leading to osteolytic bone disease, hypercalcemia, anemia, and renal dysfunction. Daratumumab was the first monoclonal anti-CD38 antibody approved for the treatment of MM, initially in relapse/refractory settings and, more recently, for newly diagnosed patients. Increased first-line usage of daratumumab will also substantially change treatment approaches for patients with relapsed/refractory disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!